MedTrace Logo

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

NCT05253911 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2025-12-04

No results posted yet for this study

Summary

The objective of this non-interventional study (NIS) is to evaluate tucatinib (TUKYSA®) combined with trastuzumab and capecitabine in adult patients with locally advanced or metastatic HER2-positive breast cancer who have been previously treated with at least two anti-HER2 treatment regimens in a real-world setting,

Conditions

Interventions

DRUG

TUKYSA®

tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.

Sponsors & Collaborators

  • Seagen Germany GmbH (a Pfizer company)

    collaborator UNKNOWN

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Anja Welt, PD Dr. · Universitätsklinikum Essen, Innere Klinik (Tumorforschung)

  • Rupert Bartsch, Assoc. Prof. PD Dr. · Medical University of Vienna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-21
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05253911 on ClinicalTrials.gov